Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beverly L Falcon

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pharmacology & Therapeutics|June 12, 2016
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agentsBeverly L Falcon, Sudhakar Chintharlapalli, Mark T Uhlik, et al.
The American Journal of Pathology|June 7, 2011
Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-BBeverly L Falcon, Kristian Pietras, Jeyling Chou, et al.
Cancer Research|March 3, 2011
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitorsBeverly L Falcon, Sharon Barr, Prafulla C Gokhale, et al.
Drug Discovery Today|September 5, 2012
High-content multiplexed tissue imaging and quantification for cancer drug discoveryBeverly L Falcon, Julie Stewart, Scharri Ezell, et al.
The American Journal of Medicine|March 22, 2026
Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysisLouis J Aronne, Deborah B Horn, Alexander D Kokkinos, et al.
Plos One|September 12, 2014
An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factorsBeverly L Falcon, Michelle Swearingen, Wendy H Gough, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaCaitlin D Lowery, Alle B VanWye, Michele Dowless, et al.
The New England Journal of Medicine|May 12, 2025
Tirzepatide as Compared with Semaglutide for the Treatment of ObesityLouis J Aronne, Deborah Bade Horn, Carel W le Roux, et al.
Journal of Hematology & Oncology|April 30, 2013
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibitionBeverly L Falcon, Belinda O'Clair, Don McClure, et al.
Molecular Cancer Therapeutics|February 22, 2019
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor InhibitionAnthony S Fischl, Xiaoen Wang, Beverly L Falcon, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmacology & Therapeutics|June 12, 2016
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agentsBeverly L Falcon, Sudhakar Chintharlapalli, Mark T Uhlik, et al.
The American Journal of Pathology|June 7, 2011
Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-BBeverly L Falcon, Kristian Pietras, Jeyling Chou, et al.
Cancer Research|March 3, 2011
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitorsBeverly L Falcon, Sharon Barr, Prafulla C Gokhale, et al.
Drug Discovery Today|September 5, 2012
High-content multiplexed tissue imaging and quantification for cancer drug discoveryBeverly L Falcon, Julie Stewart, Scharri Ezell, et al.
The American Journal of Medicine|March 22, 2026
Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysisLouis J Aronne, Deborah B Horn, Alexander D Kokkinos, et al.
Plos One|September 12, 2014
An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factorsBeverly L Falcon, Michelle Swearingen, Wendy H Gough, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaCaitlin D Lowery, Alle B VanWye, Michele Dowless, et al.
The New England Journal of Medicine|May 12, 2025
Tirzepatide as Compared with Semaglutide for the Treatment of ObesityLouis J Aronne, Deborah Bade Horn, Carel W le Roux, et al.
Journal of Hematology & Oncology|April 30, 2013
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibitionBeverly L Falcon, Belinda O'Clair, Don McClure, et al.
Molecular Cancer Therapeutics|February 22, 2019
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor InhibitionAnthony S Fischl, Xiaoen Wang, Beverly L Falcon, et al.
Pageof 2